Back to Search
Start Over
PREDICTORS OF MORTALITY AND CLINICAL CHARACTERISTICS AMONG CARBAPENEM-RESISTANT OR CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE BLOODSTREAM INFECTION IN SPANISH CHILDREN
- Publication Year :
- 2020
- Publisher :
- Cold Spring Harbor Laboratory, 2020.
-
Abstract
- BackgroundCarbapenem-resistant Enterobacteriaceae (CRE) are an emerging problem in the paediatric population worldwide with high mortality rates in bloodstream infection (BSI).ObjectivesTo evaluate predictors of 30 day mortality in CRE BSI in a paediatric cohort.MethodsA retrospective observational single-centre study (December 2005–August 2018) was conducted. Cases of CRE BSI in children 0 to 16 years were included. Microbiological identification (MALDI Biotyper) and antimicrobial susceptibility testing (Vitek2® and MicroScan panel NBC44) according to EUCAST breakpoints were performed. PCR OXVIKP® was used to confirm carbapenemase genes (OXA-48, VIM, KPC, NDM). Demographic characteristics, underlying diseases, source of bacteraemia, antimicrobial therapy and outcomes were collected from medical records. Survival analysis to establish predictors of 30 day mortality was performed.ResultsThirty-eight cases were included; 76.3% were hospital-acquired infections and 23.7% related to healthcare. All patients had at least one underlying comorbidity and 52.6% were recipients of an organ transplant. VIM carbapenemase was the predominant mechanism (92.1%). Previous CRE colonization or infection rate was 52.6%. Intestinal tract (26.3%) and vascular catheter (21.1%) were the most common sources of infection. Crude mortality within 30 days was 18.4% (7/38); directly related 30 day mortality was 10.5%. Conditions associated with an increment in 30 day mortality were intensive care admission and inadequate empirical therapy (P ConclusionsCRE BSI mortality rate is high. The most important factor related to 30 day survival in our CRE BSI cohort in children was empirical treatment that included at least one active antibiotic.
- Subjects :
- 0301 basic medicine
Microbiology (medical)
medicine.medical_specialty
medicine.drug_class
030106 microbiology
Antibiotics
Carbapenem-resistant enterobacteriaceae
Meropenem
beta-Lactamases
03 medical and health sciences
0302 clinical medicine
Bacterial Proteins
Sepsis
Intensive care
Internal medicine
medicine
Humans
Pharmacology (medical)
030212 general & internal medicine
Child
Survival analysis
Retrospective Studies
Pharmacology
business.industry
Mortality rate
Medical record
Enterobacteriaceae Infections
bacterial infections and mycoses
medicine.disease
Comorbidity
Anti-Bacterial Agents
Carbapenem-Resistant Enterobacteriaceae
Infectious Diseases
Carbapenems
Bacteremia
Cohort
business
Empiric therapy
medicine.drug
Subjects
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....b6fac34a1ced825cdebbf385454955c4
- Full Text :
- https://doi.org/10.1101/2020.05.14.20097188